Background/Aims: Angiotensin II (Ang II) is an octapeptide hormone that plays a significant role in mediating hypertension. Although hypertension is considered a chronic inflammatory disease, the molecular basis of the sterile inflammatory response involved in hypertension remains unclear. Methods: We investigated the role of macrophage NLRP3 inflammasomes in engulfing and digesting microbes, a key macrophage function, and in early onset of hypertension-associated macrophage injury using biochemical analyses, gene silencing, molecular biotechnology, immunofluorescence, and microbiology. Results: Ang II stimulation decreased nitric oxide (NO) release and macrophage digestion in cultured THP-1 cells and markedly increased NLRP3 inflammasome formation and activation. NO release and macrophage digestion were restored by NLRP3 inflammasome inhibition with isoliquiritigenin and gene silencing. This Ang II-induced upregulation of NLRP3 inflammasomes in macrophages was attributed to lysosomal damage and release of cathepsin B. Mechanistically, losartan, a nonpeptide Ang II receptor antagonist, decreased Ang II-induced NLRP3 inflammasome activation, lysosomal membrane permeability, lysosomal cathepsin B release, and macrophage digestion dysfunction. Similarly, Ang II-induced macrophage microbe digestion and NO production, which were blocked by ATI gene silencing. In addition, in vivo experiments showed that the bacteria scavenging function was clearly decreased in macrophages from Ang II-induced hypertensive mice. Conclusion: Angiotensin II enhances lysosomal membrane
Introduction
The NLRP3 (nucleotide-binding domain and leucine-rich repeat pyrin domain containing 3) inflammasome, which belongs to the nucleotide-binding and oligomerization domain-like receptor (NLR) family, plays a critical role in the pathogenesis of cardiovascular diseases, including hypertension, hypercholesterolemia, and hyperglycemia [1] [2] [3] . As a pattern recognition receptor, NLRP3 is upregulated by stimulation with pathogen-associated molecular patterns (PAMPs) [4] , which are recruited by the adapter protein apoptosisassociated speck-like protein containing CARD (ASC), and then converts pro-caspase-1 into cle-caspase-1 (cleaved form) [5] . NLRP3 inflammasome activation transforms proinflammatory cytokines such as interleukin (IL)-1β and IL-18 from their immature "pro" forms to their active forms, which have different effects in different cell types, including phenotypic transformation, cell pyroptosis, and cell membrane permeability [6] [7] [8] . In macrophages, NLRP3 inflammasome activation is critical in the formation of foam cells and other atherosclerotic lesions in response to proatherogenic stimuli such as cholesterol crystals [9, 10] . However, it remains unclear whether the activated NLRP3 inflammasomes play a critical role in the macrophage dysfunction induced by angiotensin II (Ang II) stimulation and how activated NLRP3 inflammasomes lead to macrophage injury and ultimately hypertensive complications.
In this regard, Ang II is a component of the intrarenal renin-angiotensin system (RAS) that regulates numerous renal processes such as hemodynamics and transport and that is a key factor in maintaining blood pressure homeostasis [11] . Recent work suggested that an RAS disorder, particularly elevated Ang II, is correlated with increased expression of pro-inflammatory cytokines [12] and reactive oxygen species (ROS), which cause the endothelial dysfunction implicated in hypertension-associated vascular diseases [13, 14] . Indeed, angiotensin receptor blockers have become the first-line medication for the treatment of hypertensive diseases and protect various organs against damage in many hypertensive animal models [15] . Furthermore, there is strong evidence that Ang II induces oxidative stress in macrophages, which is the crucial risk factor for the development of various hypertension-associated pathologies [16] . In addition, macrophage dysfunction is a pathological change induced by risk factors for hypertensive complications [17] . However, the role of Ang II-induced hypertension in NLRP3 inflammasome activation of macrophages remains unknown.
We hypothesized that Ang II-induced NLRP3 inflammasome activation primarily acts through lysosome destabilization-mediated signaling and thereby results in macrophage digestion dysfunction. To test this hypothesis, we first determined whether the NLRP3 inflammasome in macrophages is formed and activated in response to Ang II. We then revealed its role in lysosomal damage and release of cathepsin B in Ang II-induced NLRP3 inflammasome activation and macrophage digestion dysfunction. Using in vivo animal experiments, we examined whether Ang II stimulation was associated with macrophage digestion dysfunction. Our results show that NLRP3 inflammasome activation in macrophages during Ang II stimulation may trigger and promote macrophage digestion dysfunction during hypertension and that lysosomal stabilization is critical for macrophage digestion function due to its ability to inhibit inflammasome activation.
Phagocytosis and bacteria killing assays THP-1 cells were pretreated with Ang II for 24 h followed by E. coli (MOI 100) in serum-free DMEM for 3 h at 37°C in a humidified 5% CO 2 incubator. For phagocytosis assays, the cells were washed three times with PBS to eliminate extracellular bacteria. For bacteria killing assays, the cells were incubated in serumfree DMEM with 200 μg/ml gentamicin after 12 h. To determine bacterial content in the phagocytosis and bacteria killing assays, cells were lysed with 0.1% saponin for 15 min, serially diluted, plated onto LB agar plates, and incubated at 37°C for 18 h. The colony-forming units (CFUs) of bacteria were determined by the number of colonies formed as described previously [18] .
Nitric oxide assay THP-1 cells were prepared as described above. Nitric oxide (NO) in culture medium was measured by the Griess reaction method. Briefly, the culture supernatants were mixed with Griess reagent (Beyotime, Shanghai, China) for 10 min at room temperature. The absorbance was measured at 540 nm using a microplate reader. The nitrite content was expressed as a percentage of the untreated control.
ROS assay
THP-1 cells were treated as described above and intracellular ROS was measured by DCFH-DA. Briefly, the cells were washed three times with PBS and incubated with DCFH-DA (1:1000) for 30 min, then digested using 0.25% trypsin and washed three times with ice-cold DMEM solution to remove the remaining fluorescence dye. The excitation and emission wavelengths used in the flow cytometry were adjusted to 488 and 525 nm. 
Assessment of cellular cathepsin B activity
Cathepsin B activities in THP-1 cells were determined via measurement of the cleavage of enzymespecific, fluorogenic substrates in cell lysates using commercially available assay kits (BioVision, San Francisco, California). The fluorescent cathepsin B substrate was then used to stain the cells, Hoechst stain was used to label the cell nuclei, and acridine orange was used to identify lysosomes (Enzo, Farmingdale, New York), following the manufacturer's instructions.
Western blot analysis
Total protein was extracted using RIPA buffer (Thermo Fisher Scientific, Waltham, MA). The supernatant was obtained after centrifugation at 10, 000 × g for 15 min at 4°C and its protein concentration was measured with the BCA Protein Assay Kit (Beyotime). Cell homogenates were denatured with reducing Laemmli SDS sample buffer and boiled in a water bath for 5 min at 95°C. Equal amounts of the protein samples were separated by 12% SDS-PAGE and transferred onto PVDF membrane. The membrane was incubated in primary antibodies at 4°C overnight and then treated with anti-rabbit IgG Immunofluorescence microscopic analysis THP-1 cells adherent to round glass coverslips were fixed with 4% buffered paraformaldehyde and permeabilized with 0.1% Triton X-100. Then, the cells were stained using goat anti-NLRP3 (1:200; Abcam, Cambridge, UK), mouse anti-caspase-1 (1:200; Santa, Massachusetts, USA), or rabbit anti-ASC (1:100, Santa). After incubation with primary antibodies, the samples were washed and labeled with the corresponding Alexa Fluor-488-and Alexa Fluor-555-conjugated secondary antibodies (Invitrogen). The cells were visualized with a Zeiss LSM800 microscope (Oberkochen, Germany). Colocalization was analyzed by Image Pro Plus software, and the colocalization coefficient is presented as the Pearson's correlation coefficient.
RNA isolation and real-time quantitative PCR
Total RNA was isolated from the cells with RNAiso Plus (Takara, Kusatsu, Japan) and the concentration of extracted RNA was measured spectrophotometrically at 260 nm. The RNA quality was assessed by the ratio of absorbance at 260 and 280 nm; A260/A280 values from 1.9 to 2.1 were considered acceptable. Total RNA was reverse transcribed into cDNA using a PrimeScript RT reagent kit with gDNA Eraser (Takara). Real-time PCR was performed with SYBR Green (Takara) following the manufacturer's instructions. The primers were synthesized as follows: 5′-AGGAGAATGGACCTGCAAGC-3′ (forward primer) and 5′-TCTACCATCATCCAGCCTTGG-3′ (reverse primer) for the mouse NLRP3 gene; 5′-GGCGAGAGAGGTGAACAAGG-3′ (forward primer) and 5′-GCCAAGGTCTCCAGGAACAC-3′ (reverse primer) for the mouse caspase-1 gene; 5′-GGCGAGAGAGGTGAACAAGG-3′ (forward primer) and 5′-GCCAAGGTCTCCAGGAACAC-3′ (reverse primer) for the mouse ASC gene; and 5′-CCCATCTATGAGGGTTACGC-3′ (forward primer) and 5′-TTTAATGTCACGCACGATTTC-3′ (reverse primer) for β-actin (used as an internal reference control). The reactions were run at 50°C for 2 min and 95°C for 10 min, followed by 45 cycles at 95°C for 15 s and 60°C for 1 min on an Applied Biosystems Step-One Fast Real-Time PCR system. The results were quantified using the 2 -ΔΔCT method.
Plasmid construction and nucleofection
The gRNA sequences for the CRISPR/Cas9 genes of NLRP3 and ATR1 were designed by the CRISPR Design tool (http://crispr.mit.edu/). Then, the NLRP3 and ATR1 gRNA sequences (the NLRP3 gRNA sequence was 5'-GACGAGTGTCCGTTGCAAGC-3' and ATR1 gRNA sequence was 5'-CTTTCTTCTAAATCTCGCCC-3') were synthesized and inserted into the BbsI-digested px459 plasmid. Gene editing in cells was performed by Lipofectamine 3000 transfection according to the manufacturer's instructions (Invitrogen). Briefly, THP-1 cells were spread to more than 80% confluency and incubated in serum-free DMEM for 30 min. The plasmid master mix was prepared by dilution in Opti-MEM™ Medium (Gibco). P3000™ and Lipofectamine™ 3000 reagent were then added for 15 min at room temperature. The transfected cells were incubated in medium 
Animal procedures
Male C57BL/6N mice (8 weeks of age) weighing approximately 20-22 g were purchased from Vital River Laboratory Animal Technology Co. (Beijing, China). The mice were housed in individual ventilated cages and received food and water. The laboratory temperature was 25±2°C, the relative humidity was 50%±5%, and the animals were maintained on a 12 h/12 h light/dark cycle. The mice were housed for 7 days to adapt to the environment before experimentation. The mice were anesthetized with 10% w/v chloral hydrate by peritoneal injection for subcutaneous implantation of an osmotic mini-pump (Alzet 1007D; Charles River, Wilmington, MA) delivering 1.5 ng Ang II (Sigma) per minute and per gram body weight or a sham implantation for 5 days as described [19] . The mice were trained daily before the operation to have blood pressure determined with a computerized tail cuff system (BP-2000; Apex, New York , USA). Blood pressure was measured in conscious mice via the tail cuff, with three measurements per animal for each recording [20] .
In vivo scavenging bacteria assay Live E. coli liquid was prepared with aseptic saline and injected into the mouse tail vein at a bacterial concentration of 2 × 10 7 CFU/g. Three hours later, cardiac blood was extracted and mononuclear cells were isolated by density gradient centrifugation. Briefly, the blood sample was layered onto Ficoll-Paque PLUS (Miltenyi Biotec, Gladbach, Germany) and centrifuged at 400g for 30 min at 18°C. Then, the upper layer was removed and the lymphocyte layer was transferred according to the manufacturer's instructions. The lymphocytes were lysed with 0.1% saponin for 15 min, serially diluted, plated onto LB agar plates, and incubated at 37°C for 18 h. CFUs of bacteria were determined by the number of colonies formed [21] .
Statistical analysis
Results were expressed as mean ± SEM and analyzed using SPSS 21.0. The LSD test or Dunnett's test was used for multiple groups based on homogeneity of variance. P<0.05 indicated statistical significance.
Results

Ang II treatment affects macrophage digestion function and NO release
Macrophages are cells of the innate NO synthase/ROS system [22] . The cytotoxicity of THP-1 cells incubated with E. coli (MOI 100) and Ang II (10 μM) was determined by assessment of viable cell counts using YOYO-1; the cytotoxicity of the cells was not different from that of control cells after 3 h (Fig. 1A and B) . In addition, the proliferation of THP-1 cells incubated with Ang II (0-20 μM) was not significantly different after 24 h, as determined by the MTT method (Fig. 1C) . However, LDH leakage and cell death significantly increased with incubation with E. coli and Ang II for 24 h (data not shown). NO production was significantly decreased in Ang II-induced THP-1 cells compared with control cells (Fig. 1D) . Finally, The role of Ang II in function of macrophage bacterial phagocytosis and digestion was detected by CFU assay. Then function of macrophage bacterial phagocytosis was not significant difference, however the function of macrophage bacterial digestion was obviously decline under Ang II treatment (Fig. 1E) .
Ang II stimulation leads to formation and activation of the NLRP3 inflammasome complex in THP-1 cells
The NLRP3 inflammasome is the principal machinery triggering inflammatory responses in macrophages [23] . We next determined whether Ang II can also induce NLRP3 inflammasome production and activation in cultured THP-1 cells by analyzing the colocalization of NLRP3 inflammasome components, the expression of NLRP3 and ASC, the cleavage of pro-caspase-1 to active caspase-1, and the production of IL-1β. Ang II concentration-dependently increased the colocalization between NLRP3 (green) and ASC (red), as shown by increased yellow staining and a higher colocalization coefficient (maximal colocalization was observed after Ang II stimulation; Fig. 2A-C) . A similar increase in colocalization and the colocalization coefficient was found for NLRP3 and caspase-1 and for NLRP3 and caspase-1. Consistent with the findings for the formation of the NLRP3 inflammasome complex, we further demonstrated that Ang II affected the expression of the NLRP inflammasome components (Fig. 2D-G) and NLRP3 inflammasome activity in THP-1 cells, as shown by enhanced cleavage of pro-caspase-1 proteins to their bioactive forms (p20 subunit) (Fig. 2H  and I ). Ang II significantly increased NLRP3 expression ( Fig. 2D and E) . We also noted that Ang II did not increase the transcription or expression of ASC (Fig. 2F and G) . Thus, Ang II treatment increased the conversion of inactive pro-caspase-1 to the active form in THP-1 cells. 
Inhibition of NLRP3 preserves macrophage digestion function
We further examined whether NLRP3 inflammasome activation by Ang II causes macrophage digestion dysfunction in THP-1 cells in vitro. As shown in Fig. 3 , NO production and bacteria killing function was damaged with Ang II (10 μM) treatment. In contrast, Ang II-induced dysfunction in THP-1 cells was prevented by the NLRP3 inhibitor ISO and in macrophages transfected with NLRP3 shRNA plasmid.
Inhibition of cathepsin B abrogates Ang II-induced NLRP3 inflammasome activation and macrophage digestion dysfunction
To directly monitor the changes in lysosome membrane permeability in live THP-1 cells, the cells were stained with the lysosomotropic agent acridine orange, which emits red fluorescence in undamaged lysosomes and no fluorescence in damaged lysosomes [24] . As shown in Fig. 4A , lysosomes in control cells were visualized as red puncta with high fluorescent intensity, whereas Ang II treatment concentration-dependently decreased the number and fluorescence intensity of red puncta. Lysosomal release of cathepsin B plays a crucial role in mediating NLRP3 inflammasome activation induced by lysosome membrane permeabilization [25] . As shown in Fig. 4A and B, we also found a marked increase in cathepsin B expression in the cytosol of THP-1 cells upon Ang II stimulation, suggesting that cathepsin B release may be a consequence of increased lysosome membrane permeability leading to NLRP3 inflammasome activation. Similarly, we found that Ca-074 abolished Ang II-induced (Fig. 4C-F) . These findings confirm that cathepsin B is involved in Ang II-induced macrophage NLRP3 inflammasome activation in vitro. Furthermore, Ca-074 markedly blocked an Ang II-induced increase in ROS and abrogated the bacteria killing and NO release of macrophages ( Fig. 4G-I ). These data suggest that inhibition of cathepsin B also blocks Ang II-induced macrophage digestion dysfunction. 
ATR1 blockade attenuates Ang II-induced macrophage NLRP3 inflammasome activation and digestion dysfunction
The AT receptor is associated with cathepsin activation [26] . To directly determine whether the changes in Ang II-induced macrophage digestion dysfunction by AT receptor caused cathepsin B release-induced NLRP3 inflammasome activation, the Ang II receptor type 1 (ATR1) blocker (LOS) and ATR1 shRNA plasmid transfection were used in THP-1 cells. LOS prevented Ang II-induced caspase-1 activation but not NLRP3 protein expression (Fig. 5A-D) . In addition, cathepsin B release and bacteria killing dysfunction was prevented ( Fig. 5E and F) . Transfection of THP-1 cells with ATR1 shRNA plasmids also prevented Ang II-induced functional damage and NO release ( Fig. 5G and H) . Consistently, these data demonstrated that the ATR1 blocker LOS prevents Ang II-induced caspase-1 activation but not NLRP3 protein expression, suggesting that LOS inhibits NLRP3 inflammasome activation in macrophages by disrupting the assembly of the NLRP3 inflammasome complex.
Macrophage digestion dysfunction is induced in mice treated with Ang II
To further determine the role of Ang II in macrophage digestion dysfunction in mice, hypertension was established by subcutaneous implantation of an osmotic mini-pump delivering Ang II into male mice. After the operation, the model mice showed a sustained elevation in systolic blood pressure and a stable level of 104.5 ± 3.4 mmHg after the second Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry day. However, the diastolic blood pressure was not significantly increased ( Fig. 6A and B) . On the fifth day, the function of scavenging bacteria was clearly decreased in macrophages from Ang II-induced hypertensive mice ( Fig. 6C and D) . These findings further indicate that Ang II is involved in the ability of macrophages to digest bacteria.
Discussion
Recent studies have shown that Ang II can induce an inflammatory response [27] and macrophage dysfunction [28] . However, the cellular physiological relevance of such NLRP3 inflammasome activation in modulating macrophage function remains largely unknown. We aimed to determine whether Ang II-induced NLRP3 inflammasome activation results in macrophage digestion dysfunction. Our data for the first time reveal that activation of NLRP3 inflammasomes by Ang II results in attenuation of the ability of macrophages to digest bacteria, which is closely connected to ATR1-mediated lysosomal dysfunction.
The importance of understanding macrophage function is underscored by consideration of the role of this multifaceted cell type in initiating an inflammatory response against a pathogen. One component central to these functions is digestion. Although macrophage phagocytosis and digestion are a complex process, many studies have illuminated the importance of the mechanisms controlling this function, such as receptor expression, small GTPases, lysosome dysfunction, actin cytoskeleton, and PI3K signaling [29] [30] [31] . The function of bacteria clearance is determined by the macrophage rate of digestion and phagocytosis. An increased clearance rate plays a marked role in macrophage physiology, which has been considered a marker event for the attenuation of anti-bacterial effects during infection. The present study revealed that stimulation of macrophages with Ang II decreased the rate of bacterial clearance, without affecting cytotoxicity, proliferation, and phagocytosis (Fig. 1) . These data reveal for the first time a critical role for Ang II in inhibiting macrophage bacteria killing.
Our data further confirmed that Ang II inhibition of macrophage bacteria killing is primarily associated with NLRP3 inflammasome formation and activation by macrophages. The NLRP3 inflammasome plays a critical role in the development of different types of chronic diseases, such as vascular diseases, aging, and chronic infections [32] [33] [34] . Through various approaches, we confirmed that Ang II stimulation induced the formation and activation of the NLRP3 inflammasome complex in cultured macrophages, as shown using confocal microscopy by colocalization of NLRP3 with ASC or caspase-1 and by biochemical analysis of caspase-1 activity (Fig. 2) . These results clearly suggest that NLRP3 inflammasomes are active in macrophages and that Ang II stimulation can lead to their activation. Interestingly, our work found that Ang II inhibited macrophage bacteria killing and NO release; this effect was abolished by NLRP3 gene silencing and NLRP3 inflammasome inhibition with ISO (Fig.  3) .
The above research indicated that Ang II induced NLRP3 inflammasome formation and activation in a concentration-dependent manner. Currently, it is generally believed that NLRP3 inflammasome activation requires two signals. Signal 1 of NLRP3 inflammasome activation involves increased NLRP3 gene transcription by NF-κB [35] . Signal 2 of NLRP3 inflammasome activation involves the induced assembly of the NLRP3 inflammasome complex, resulting in activation of caspase-1 and subsequent pro-IL-1β maturation [36] . Regarding signal 1, Ang II increased the NLRP3 gene transcription and NLRP3 protein expression but did not change the ASC level in this study. As for signal 2, we show for the first time that ROS generation and lysosome stability regulate Ang II activation of the NLRP3 inflammasome and effectuate the macrophage bacteria killing function. Similarly, a recent study demonstrated that the NLRP3 inflammasome is activated by Ang II via the Toll-like receptor 4 (TLR4)/MyD88/NF-κB pathway in hepatic fibrosis [37] . Nonetheless, our data imply that lysosome stability controls the NLRP3 inflammasome activation and functionality in response to Ang II in macrophages (Fig. 4) . The reason for the discrepancy between these Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry previous findings and our results for inflammasome activation is unclear. It appears that NLRP3 inflammasome machinery can be activated by distinct mechanisms depending on cell type and pathological condition. Previous studies have shown that Ang II can regulate cellular responses primarily via the lysosome-associated pathway, leading to pathological cardiac remodeling, by blocking muscle protein wasting, intracellular renin activity, and other cell processes [38, 39] . As a complement, we used Ca-074 to inhibit cathepsin B activation in vitro. Ca-074 significantly attenuated Ang II-induced macrophage bacteria killing dysfunction in macrophages (Fig.  4) . Our data suggest that Ang II-induced macrophage bacteria killing dysfunction is mainly associated with cathepsin B-NLRP3 inflammasome signaling in macrophages.
The AT receptor has been associated with cathepsin activation [26] . At the same time, other mechanisms may apply to Ang II-induced cellular disruption by the AT receptor in different cell systems. It should be noted that AT1 and AT2 have been reported to mediate Ang II-induced cellular dysfunction in different cell types [40] [41] [42] . Thus, it seems that the interaction of Ang II with AT1 or AT2 can activate different signaling cascades that may lead to distinct functional alterations in cells. Consistently, our data demonstrated that the ATR1 blocker LOS prevents Ang II-induced caspase-1 activation without affecting NLRP3 protein expression, suggesting that LOS inhibits NLRP3 inflammasome activation in macrophages by disrupting the assembly of the NLRP3 inflammasome complex (Fig. 5) . Ang II induces ROS production in macrophages by either eliciting Ca 2+ and ERK1/2 pathways leading to mitochondrial fission or by activating NADPH oxidases [43] . Interestingly, we found that LOS ameliorated the Ang II-induced macrophage bacteria killing dysfunction (Fig. 5) . Similarly, a recent study also demonstrated that LOS has distinct pharmacological effects on different cell types via the ATR1 pathway, such as decreased aortic root dilation by blocking deleterious Ang II-ATR1 signaling, while preserving protective Ang II-ATR1 interactions [44] . Using genetic manipulation of ATR1, we found that ART1 protein expression was significantly reduced after transfection of shRNA into cultured macrophages (data not shown). In the present study, downregulation of the ATR1 gene or LOS significantly prevented Ang II-induced NLRP3 inflammasome formation and activation in macrophages (Fig. 5) . Furthermore, our in vivo model system also showed that Ang II attenuates the ability of macrophages to digest bacteria (Fig. 6 ). To our knowledge, this is the first evidence showing the critical role of the ATR1-cathepsin B-NLRP3 pathway in mediating macrophage activity against a pathogen in response to Ang II stimulation.
Conclusion
In summary, we demonstrated that activation of NLRP3 inflammasomes by Ang II inhibited macrophage bacteria killing in vitro. In addition, Ang II activated the NLRP3 inflammasome by regulating ROS generation and lysosome stability. In a mouse model of Ang II-induced hypertension, hypertension disrupted macrophage bacteria killing in the blood after treatment of the mice with bacteria. Our results reveal a novel direct action of the macrophage NLRP3 inflammasome on the development of macrophage dysfunction and injury during the early stage of hypertension disorders.
Cellular Physiology and Biochemistry
Cellular Physiology and Biochemistry
